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March 16, 2010:1163–7verall load imposed on the LV, it fails to guide clinicians in
ssessing the relative significance of these commonly coexisting
roblems. Besides, Zva may not be able to discriminate adequately
etween a severe AS with mild hypertension and a mild-to-
oderate AS with severe hypertension causing hypertension-
nduced left ventricular (LV) dysfunction, thus will fail in assessing
he real severity of AS.
The authors do not provide information about the clinical
ourse, time of appearance of classic AS symptoms (angina,
yncope, and heart failure), sudden cardiac death, or treatment of
tudy patients, to answer the most vexing question of proper
iming of surgery on these patients in order to outweigh the risks
f surgery and a prosthetic valve (2).
On the basis of the present information, the role of Zva as a tool
or assessing the prognosis in isolation seems controversial because
t is difficult to conclude that more deaths in the high-Zva group
re attributable mainly to AS. Patients in this group were signif-
cantly older and had a higher prevalence of hypertension. A high
va might have been a reflection of a higher blood pressure, and
ay not be truly indicative of high risk due to AS. This is further
upported by the fact that the survival was lower in the high-Zva
roup even after aortic valve replacement when compared with
ower-Zva groups.
One can further suggest that patients in the high Zva group
atients may also have had a higher prevalence of atrial fibrillation
although no information was available for this common problem),
hich may also have contributed to the poor outcome, as com-
ared with younger patients in the low- and medium-Zva groups.
The investigators have suggested that if Zva remains 3.5 mm
g·ml1 m2 on re-evaluation after treatment of hypertension in
ymptomatic patients with moderate AS, then symptoms can be
ttributed to moderate AS. It remains to be proven that normal-
zation of blood pressure in the short term is adequate for the
eversal of hypertension-induced chronic changes in ventricles and
rteries for a high Zva to be reflective of LV load imposed solely by
S. At the present time, it does not seem prudent to combine
lood-pressure–induced changes with the indexes of AS severity in
linical decision making because correct interaction of blood
ressure and AS is far from clear from the available data (3,4).
Regardless of these limitations, the concept of Zva certainly
ighlights the need for adequate blood pressure control in these
atients to reduce the pressure burden on the LV and to identify
atients with paradoxical low-flow AS who might benefit from
arly valve replacement (5,6).
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eply
e thank Drs. Naqvi and Samarendra for their interest in our
ork (1). We wholeheartedly agree with Dr. Naqvi that diastolic
ysfunction is an integral part of the pathophysiology of patients
ith increased valvuloarterial impedance (Zva). This was empha-
ized in the introduction of this report referring to our first report
escribing this parameter (2) as well as in our recent review article
n this topic (3). Indeed, left ventricular (LV) concentric remod-
ling and the development of a smaller LV cavity is akin to a
estrictive physiology and by definition within the spectrum of
iastolic dysfunction because the primary consequence is decreased
V filling. Per se, this type of geometric remodeling results in
ecreased LV compliance and a shift of the LV diastolic pressure–
olume curve to the left. In addition, it may well be that the
resence of interstitial myocardial fibrosis may yet contribute to
urther decrease LV compliance. As we also previously empha-
ized, the presence of paradoxical low flow in this context is indeed
ue to a problem of LV filling rather than LV emptying.
It should also be emphasized that from a pathophysiological
tandpoint, the main determinant of the development of LV
oncentric remodeling/hypertrophy and of LV diastolic (and
ubsequently systolic) dysfunction is the magnitude of the hemo-
ynamic burden imposed by AS and/or hypertension on the LV.
ence, increased global LV load is at the source of the cascade
eading to the development of LV diastolic and systolic dysfunc-
ion. Therefore, it is logical that Zva, which precisely reflects the
lobal hemodynamic load, comes out as a powerful independent
redictor of survival even after adjusting for other indexes of LV
ysfunction.
With regard to Dr. Samarendra’s concerns, we thought we had
ade it perfectly clear in the report that, per se, Zva does not
eparate the relative contributions of aortic stenosis (AS) and the
ssociated hypertension, and hence we have never proposed that it
hould be used in isolation as a standalone parameter. As empha-
ized in our conclusion, it does nonetheless provide valuable and
itherto unavailable information that must, however, be inter-
reted within the context of a comprehensive evaluation including
he usual indexes of AS severity. In particular and as recognized by
r. Samarendra, it allows the identification of paradoxical low-
ow AS, a frequent condition that was previously largely undiag-
osed and carried a very poor prognosis if not treated surgically
3–5). In these patients, both the transvalvular gradient and the
ystolic blood pressure may be pseudonormalized due to the
eduction in LV output and transvalvular flow. This highly
nsidious situation may lead the clinician to substantially underes-
imate the presence and severity of AS and/or hypertension and
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March 16, 2010:1163–7hereby the global hemodynamic burden imposed on the LV. In
his context, the calculation of Zva allows the detection of patients
aving an abnormally high hemodynamic load occulted by para-
oxical low flow and associated pseudonormalization of gradient
nd blood pressure. The Zva also provides more insight into the
athophysiology of symptomatic patients with the combination of
ypertension and less-than-severe AS. In the discussion, we have
onetheless emphasized that in this situation future studies are
ecessary to determine how these findings can be translated into
linical practice to improve the diagnosis, treatment, and prognosis.
In time, the development of LV dysfunction and the occurrence
f adverse events (including symptoms, atrial fibrillation, heart
ailure, cardiovascular deaths, and so on) should logically be related
o the global hemodynamic burden imposed by AS and/or hyper-
ension on the LV and upstream cardiac chambers. We thus
elieve that the first essential step in the evaluation of these
atients is to estimate the global hemodynamic load to determine
hether the patient is at risk for poor outcome. The Zva is
articularly useful in this regard as it provides a simple and
oninvasive parameter for estimating the global load and predict-
ng outcomes. The second step is then to dissect the respective
ontributions of AS and hypertension to the increased global
urden by examining the indexes of the valvular and arterial loads,
espectively. To this effect, the clinician should be cautious about
he use of transvalvular gradient and blood pressure for clinical
ecision making because these indexes may be pseudonormalized.
hey should preferably use indexes that are less flow dependent,
uch as the aortic valve area or energy loss index for assessment of
alvular load and arterial compliance and vascular resistance for the
ssessment of arterial load.
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-Type Natriuretic Peptide
ssay to Diagnose Significant
ardiovascular Disease
n Children
e read with interest the paper of Law et al. (1) regarding the
ccuracy of B-type natriuretic peptide (BNP) to diagnose signifi-
ant cardiovascular disease in children. In their prospective study
he authors enrolled 100 children (including 42 neonates) present-
ng with signs and symptoms that might be attributable to
ardiovascular abnormalities. Their results clearly showed how the
se of BNP was helpful in discriminating children with structural
r functional cardiovascular diseases. They indicated how, up to 7
ays of life, the cutoff of 170 ng/l had a positive predictive value of
1% in ruling out cardiac disease, whereas in older children a BNP
alue of 41 ng/l had a positive predictive value of 77%. Plasma
NP was measured with a point-of-care testing method (Triage
NP, Biosite, Inc., San Diego, California).
On the basis of our experience, we appreciate and encourage the
dea to use BNP in the integrated approach of newborns and
hildren with suspected cardiovascular diseases. However, we
elieve that the use of 2 different cutoffs—1 for newborns up to 7
ays and the other for all the other children—might represent an
versimplification. We assessed the reference interval limits of
NP assay in newborns and infants in a wide population of healthy
ubjects, with the same triage BNP method, performed on the fully
utomated Access platform (Triage BNP reagents, Access Immu-
oassay Systems, REF 98200, Beckman Coulter, Inc., Fullerton,
alifornia) (2). Plasma BNP was measured in 190 apparently
ealthy newborns and infants throughout the first month of
xtra-uterine life, as well as in 184 healthy infants, with ages
anging from 1 month to 12 years. The BNP showed the highest
evels in the first 2 days of life (median 229.0 ng/l, range 41 to 866
g/l, 97.5th percentile, 745 ng/l, n 91) with a progressive decline
n the next days (BNP values from 49 to 190 h of life: median
10.0 ng/l, range 10 to 739 ng/l, 97.5th percentile, 480 ng/l, n 
9). Moreover, due to the great variability of circulating levels, the
iagnostic accuracy of BNP assay might be significantly lower in
he first days of life, especially if incorrect cutoff values are taken
nto account. Considering the 97.5th percentile as a possible
pper limit for the reference interval, we propose 3 different
ecision levels for the diagnosis of cardiovascular disease in
hildren: 1 for the first 2 days of life (i.e., 750 ng/l), 1 from the
hird to seventh day (i.e., 480 ng/l), and the other from 2 weeks
o 10 years (i.e., 45 ng/l).
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